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OBJECTIVE — To minimize hypoglycemia in subjects with type 1 diabetes by automated
glucagon delivery in a closed-loop insulin delivery system.
RESEARCH DESIGN AND METHODS — Adult subjects with type 1 diabetes under-
went one closed-loop study with insulin plus placebo and one study with insulin plus glucagon,
given at times of impending hypoglycemia. Seven subjects received glucagon using high-gain
parameters, and six subjects received glucagon in a more prolonged manner using low-gain
parameters. Blood glucose levels were measured every 10 min and insulin and glucagon infu-
sions were adjusted every 5 min. All subjects received a portion of their usual premeal insulin
after meal announcement.
RESULTS — Automated glucagon plus insulin delivery, compared with placebo plus insulin,
signiﬁcantly reduced time spent in the hypoglycemic range (15  6 vs. 40  10 min/day, P 
0.04). Compared with placebo, high-gain glucagon delivery reduced the frequency of hypogly-
cemic events (1.0  0.6 vs. 2.1  0.6 events/day, P  0.01) and the need for carbohydrate
treatment (1.4  0.8 vs. 4.0  1.4 treatments/day, P  0.01). Glucagon given with low-gain
parameters did not signiﬁcantly reduce hypoglycemic event frequency (P  NS) but did reduce
frequency of carbohydrate treatment (P  0.05).
CONCLUSIONS — During closed-loop treatment in subjects with type 1 diabetes, high-
gain pulses of glucagon decreased the frequency of hypoglycemia. Larger and longer-term
studies will be required to assess the effect of ongoing glucagon treatment on overall glycemic
control.
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S
evere hypoglycemia is an acute
complication of insulin therapy
that can lead to seizures, coma,
and death (1) and creates a barrier to
optimal glycemic control in diabetes
management (2). Despite treatment ad-
vances such as insulin pump therapy
and continuous glucose monitoring,
hypoglycemia remains a concern, even
when insulin is given in a closed-loop
system (3). Here, we report on a novel,
automated, sensor-controlled method
of insulin delivery accompanied by glu-
cagon delivery at times of impending
hypoglycemia.
A closed-loop system consists of a
glucose-measuring device, from which
data are collected and entered into an al-
gorithm, which in turn controls insulin
delivery (4). The difﬁculty of delivering
regularoranaloginsulininsuchamanner
is related to its slow onset and prolonged
effect when delivered subcutaneously.
Until a more rapidly acting insulin prep-
aration is available, discontinuation of
subcutaneous insulin during impending
hypoglycemia, with any algorithm, may
be insufﬁcient to prevent hypoglycemia.
Glucagon, a hormone secreted from
the -cells of the normal endocrine pan-
creas, rapidly raises circulating glucose
levels within minutes via glycogenolysis,
even when given subcutaneously (5).
Glucagon is approved for use as a paren-
teral injection for treatment of severe hy-
poglycemia. In children, an off-label use
has been described using small subcuta-
neous doses to prevent or treat mild hy-
poglycemia (6,7).
In 1982, Shichiri et al. (8) published
the concept of including glucagon deliv-
eryinanautomatedclosed-loopglycemic
controlsystem.Morerecently,suchasys-
tem has been studied in animals by our
group (9) and by the Boston University
group (10) with promising results. In this
study of subjects with type 1 diabetes, we
compared the frequency and duration of
hypoglycemia during treatment with in-
sulin plus glucagon to treatment with in-
sulinplusplacebo.Deliveryofinsulinand
glucagon was automated and controlled
by an amperometric glucose sensor. We
hypothesized that when given for im-
pending hypoglycemia, glucagon would
decrease the frequency of overt hypogly-
cemia more than placebo.
RESEARCH DESIGN AND
METHODS— Patients were recruited
from the Oregon Health and Science Uni-
versity (OHSU) outpatient clinics in Port-
land, Oregon. Patients who were
pregnant or had cardiovascular, cerebro-
vascular, kidney, or liver disease or any
other uncontrolled chronic medical con-
ditions were excluded. Other exclusion
criteria included oral or parenteral corti-
costeroid use, immunosuppressant use,
visual or physical impairments that im-
pede the use of a continuous glucose-
monitoring device, insulin or glucagon
allergy, hypoglycemia unawareness or
hospitalization within the past 2 years for
severe hypoglycemia, serum insulin anti-
body titer 100 U/ml, or requirement
of 200 units insulin/day. The research
protocol was approved by the OHSU In-
stitutional Review Board, and all subjects
provided written informed consent. Per-
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granted by the U.S. Food and Drug Ad-
ministration (FDA) (investigational de-
vice exemption no. G080130).
Atotalof22closed-loopstudiesin14
subjectswereperformed.Agewas36.7
3.7 years, with a duration of diabetes of
14.1  3.1 years. A1C was 7.6  0.3%
and BMI 27.8  1.5 kg/m
2. The study for
one patient was stopped early because of
repeated intravenous catheter failures.
The data from this study were excluded
from the analysis, leaving 21 datasets
from 13 subjects.
As requested by the FDA, ﬁve sub-
jects participated in single 9-h studies
with both insulin and glucagon to assess
the safety and effectiveness of the study
protocol. Eight subjects underwent one
study with insulin and placebo and one
with insulin and glucagon (see Fig. 1). Of
the13studiesduringwhichglucagonwas
given,itwasdeliveredusinghigh-gainpa-
rameters in seven studies and using low-
gain parameters in six. Low- versus high-
gainglucagonisdiscussedindetailbelow.
The treatment order of each paired study
was determined by a randomization
scheme. In paired studies, subjects were
blinded as to whether they received glu-
cagon or placebo.
Subjects wore two subcutaneous glu-
cose sensors, either DexCom Seven Plus
or Medtronic Guardian Real-Time glu-
cose sensors. Sensors were placed 8–24 h
prior to beginning the study. For subjects
taking long-acting insulin at night, the
dose was reduced by 50% the night prior
tothestudy.Thefollowingmorning,sub-
jectswereadmittedtotheOregonClinical
and Translational Research Institute at
OHSU. An intravenous catheter was
placedinaforearmvein.Theforearmwas
warmed with a heating pad to arterialize
the venous blood. Venous glucose was
measuredevery10mininduplicateusing
a HemoCue Glucose 201 Analyzer. Glu-
cose sensor readings were recorded from
thereceiversevery5min.Fortheﬁrst2h,
the insulin and glucagon delivery rates
were determined by venous glucose lev-
els. After the ﬁrst 2 h, the sensed glucose
values from the sensor with better accu-
racywereinputintothealgorithmevery5
min to determine the hormone delivery
rates. If the sensor accuracy became sub-
optimal,deﬁnedasamedianabsoluterel-
ative difference (MARD) exceeding 20%
or median absolute difference (MAD) ex-
ceeding20mg/dl,controlwasswitchedto
the other sensor. If the accuracy of both
sensorswaspoor,controlwasswitchedto
venousglucoseandthesensorswerereca-
librated.Sensorswerecalibratedatamin-
imum of every 12 h.
TheFadingMemoryProportionalDe-
rivative (FMPD) algorithm (9,11) was
used to determine the insulin and subcu-
taneous glucagon (or placebo) delivery
rates. Aspart insulin (Novo Nordisk) was
delivered subcutaneously via an Animas
IR1000insulinpump.Glucagonorsaline
placebo was given through a subcutane-
ouscatheterviaaMedfusion2001syringe
pump. One milligram of glucagon (Novo
Nordisk) was mixed with 3 ml of sterile
water. The glucagon preparation was
freshly reconstituted every 8 h. A study
physician was onsite at all times and had
the ability to override the hormone infu-
sion rates called for by the FMPD algo-
rithm, which occurred only 1.7% of the
time. Either a registered nurse or physi-
cian was responsible for adjusting the in-
sulin delivery rate and glucagon delivery
rate every 5 min, based on the controller
output.
The FMPD algorithm determined the
hormone delivery rates based on propor-
tional error, deﬁned as the difference be-
tween the current glucose level and the
target level, and the derivative error, de-
ﬁned as the rate of change of the glucose.
The “fading memory” designation refers
to weighting recent errors more heavily
than remote errors. This weighting pro-
vides an adaptive component to the algo-
rithm, as described previously (9,11). In
simple terms, the insulin rate was in-
creased for high or rising glucose levels
and glucagon was given for low or falling
glucose levels. The basal insulin infusion
rate (in units per hour) was given at a rate
of 35% of the patient’s typical total daily
insulin dose, divided by 24.
Figure 1—Study diagram depicting the number of subjects studied under each condition and the study lengths.
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In the FMPD algorithm, the gain factors
determined the degree to which propor-
tional or derivative errors led to changes
in hormone delivery rates. There were
separate gain factors for insulin and glu-
cagon. Positive proportional errors (glu-
cose level above target) and positive
derivative errors (rising glucose level)
called for an increase in the insulin deliv-
ery rate. The overall insulin delivery rate
wasdeterminedbyaddingtheratescalled
for by the proportional error (IIRpe), the
derivative error (IIRde), and the basal in-
sulin rate.
The proportional error gain factor
was1.210
30.07810
3units/kg
per mg/dl/h for glucagon studies and
1.3  10
3 units/kg per mg/dl/h for pla-
cebo studies. The derivative error gain
factor was 2.0  10
3  0.096  10
3
units/kg per mg/dl for glucagon studies
and was 2.0  10
3 units/kg per mg/dl
for placebo studies. The mean blood glu-
cose target was 110  1 mg/dl for gluca-
gon studies and 110 mg/dl for placebo
studies. There were no signiﬁcant differ-
ences between any of these parameters
betweenthegroups.Forsubjectswhoun-
derwent two closed-loop studies, the al-
gorithm parameters were identical for
both.
Insulinonboard,theamountofinsu-
lin that had been delivered and was as-
sumed to be active, was continually
estimated using a model that we derived
from data published by Holmes et al.
(12). To minimize hypoglycemia, the in-
sulin infusion was discontinued if the es-
timated insulin on board reached 15% of
the subject’s estimated total daily insulin
requirement.
Determination of glucagon delivery
The proportional and derivative error
gain factors for glucagon were negative,
such that negative proportional and de-
rivative errors called for an increase in the
glucagon rate. For glucagon, the average
weighted proportional error was calcu-
lated over a 15 min interval and the aver-
age weighted derivative error was
calculated over a 10 min interval. There
was no basal glucagon infusion rate.
In this project, we tested two closely
related algorithms for administering glu-
cagon.Foursubjectscompleted9-hstud-
ies and two subjects completed 28-h
studies with low-gain factor settings. In
these low-gain glucagon studies, the
mean proportional error gain factor was
0.23  0.04 ml/kg per mg/dl/h, the
mean derivative error gain factor was
0.06  0.009 ml/kg per mg/dl, and tar-
get glucose for glucagon infusion was
108  3 mg/dl. Two subjects completed
9-h studies and ﬁve subjects completed
28-h studies with high-gain factor set-
tings. For all of these high-gain glucagon
studies, the proportional error gain factor
was 2.70 ml/kg per mg/dl/hour, the de-
rivative gain factor was 0.60 ml/kg per
mg/dl,andthetargetglucoseforglucagon
infusionwas971mg/dl.Toavoidover-
deliveryofglucagon,whentotalglucagon
delivery over the prior 50 min reached a
ceiling of 1.0 g/kg, the algorithm initi-
ated a refractory period for the subse-
quent 50 min, during which glucagon
couldnotbedelivered.Thus,shortpulses
of glucagon delivery over 5–10 min were
followed by the absence of glucagon de-
livery for 50 min. The insulin rate was
reduced by 75% for 40 min after each
maximal glucagon pulse.
Meals
Patients were given two meals during
each 9-h study and four meals during
each 28-h study. Each meal was an-
nounced to the controller and an open
loop premeal bolus was given. Aspart in-
sulin was given 0–10 min before meals,
depending on the subject’s premeal glu-
cose level. For low-gain glucagon studies,
53.3  7.0% of usual premeal insulin
dose was given. The amount of premeal
insulin was increased after the ﬁrst four
studies because of a pattern of postpran-
dial hyperglycemia in those studies. For
all placebo and high-gain glucagon stud-
ies,75%oftheusualpremealinsulindose
was given.
Hypoglycemic treatment
Subjects were treated for hypoglycemia if
the venous glucose value fell below 70
mg/dl. For glucose levels 60–69 mg/dl,
subjects were given 15 g oral carbohy-
drate, and the treatment repeated as
needed every 15 min. For a glucose value
60 mg/dl, 10 g dextrose was given
intravenously.
Statistical analysis
Arterialized venous glucose values, not
sensed glucose values, were used to com-
pare hypoglycemia and glucose control
between groups. Glucose area under the
curve (AUC) was calculated as published
elsewhere (13). Minutes in the hypogly-
cemic range, deﬁned as glucose 70 mg/
dl, hypoglycemic events, treatments for
hypoglycemia, units of insulin delivered,
and micrograms of glucagon delivered
were normalized to 24 h for data from
both 9- and 28-h studies. Data are ex-
pressed as means  SE. Sensor accuracy
was calculated by comparing sensor glu-
cose to reference glucose values (14).
Comparisons were made using paired or
unpaired t tests, as appropriate. Calcula-
tionswereperformedusingMicrosoftEx-
cel 2007 (version 12).
RESULTS— Six women and seven
menwithtype1diabetesparticipatedina
total of 21 human closed-loop studies
with a duration of 21.5  2.0 h. Seven
subjects received glucagon delivered in a
brisk fashion (high-gain) and six subjects
received glucagon delivered in a slower
fashion (low-gain). In both the high- and
low-gain glucagon studies, glucagon was
typically delivered at times of impending
hypoglycemia when glucose was 90–120
mg/dl, depending on the rate of glucose
decline (Fig. 2). At these times, insulin
delivery was also markedly reduced or
discontinued by the insulin algorithm.
The high-gain glucagon results
(paired analysis), low-gain glucagon re-
sults (unpaired analysis), and combined
high- and low-gain glucagon results (un-
paired analysis) are presented separately
below. One subject who received high-
gainglucagonbutdidnotreturnforapla-
cebo study was included in the combined
results but was not included in the paired
high-gain analysis.
High-gain glucagon results
In six subjects who underwent both a
high-gain glucagon study and a placebo
study, there was a 56% reduction in time
spentinthehypoglycemicrange(1811
vs. 41  13 min/day, P  0.01). The
number of hypoglycemic events, with
events lasting 20 min being considered
a new event, was also signiﬁcantly re-
ducedduringthehigh-gainglucagonver-
sus placebo studies (1.0  0.6 vs. 2.1 
0.6 events/day, P  0.01), as was the
number of oral or intravenous carbohy-
dratetreatmentsforhypoglycemia(1.4
0.8 vs. 4.0  1.4 treatments/day, P 
0.01). There was no signiﬁcant difference
in mean glucose between the high-gain
glucagon versus placebo studies (138 
17vs.13117mg/dl,PNS),asshown
in Fig. 3A. The mean fasting glucose was
also quite similar (123  14 vs. 120  15
mg/dl, P  NS). There was a nonsigniﬁ-
cant trend toward a higher postprandial
glucose in high-gain glucagon versus pla-
cebo studies, deﬁned as mean value
Automated insulin and glucagon delivery
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144  17 mg/dl, P  NS). The amount of
insulin delivered during the high-gain
glucagon versus placebo studies was
nearly identical (48.9  6.2 vs. 48.3 
5.5 units per day, P  NS).
Low-gain glucagon results
Insixsubjectswhoreceivedlow-gainglu-
cagon compared with the eight subjects
whoreceivedplacebo,therewasanonsig-
niﬁcant reduction in time in the hypogly-
cemicrange(158vs.4010min/day,
P  NS). There was also a trend toward a
reductioninthenumberofhypoglycemic
events that did not reach statistical signif-
icance (1.4  0.7 vs. 2.3  0.5 events/
day, P  NS). There was a reduction in
the number of treatments for hypoglyce-
mia in studies with low-gain glucagon of
borderline signiﬁcance (1.0  0.7 vs.
3.9  1.0 treatments/day, P  0.05).
Mean glucose was somewhat higher in
low-gain glucagon versus placebo studies
(15724vs.13516mg/dl,P0.04).
Therewasalsoatrendtowardhigherfast-
ing glucose in the low-gain glucagon ver-
sus placebo studies (137  20 vs. 122 
13 mg/dl, P  NS). There was a similar
trend, of borderline statistical signiﬁ-
cance, suggesting a larger elevation in
postprandial glucose in the low-gain glu-
cagon versus placebo studies (179  26
vs.15118mg/dl,P0.05).Therewas
a nonsigniﬁcant difference in insulin de-
livered in low-gain glucagon versus pla-
cebo studies (60.1  14.1 vs. 46.9  5.5
units/day). The mean dose of glucagon
delivered during the low-gain glucagon
studieswashigherthanthehigh-gainglu-
cagon studies but did not reach statistical
signiﬁcance (746  134 vs. 516  108
g/day, P  NS).
Combined high- and low-gain
glucagon results
Glucagon, when given either via high- or
low-gain,comparedwithplacebo,ledtoa
63% reduction of time spent in the hypo-
glycemic range (15  6 vs. 40  10 min/
day, P  0.04). The number of
hypoglycemic events per day was not sig-
niﬁcantlydifferentbetweenglucagonver-
sus placebo studies (1.1  0.4 vs. 2.3 
0.5 events/day, P  NS). The number of
treatments for hypoglycemia per day was
considerablyreducedintheglucagonver-
sus placebo studies (1.1  0.5 vs. 3.9 
1.0 treatments/day, P  0.01). Mean glu-
cose was somewhat higher in the gluca-
gon studies, but this increase did not
reachstatisticalsigniﬁcance(14514vs.
135  16 mg/dl, P  NS). Other metrics
of glycemic control, including percent of
AUC in the target (70–180 mg/dl) and
hyperglycemic (180 mg/dl) ranges and
mean amplitude of glycemic excursions
were not signiﬁcantly different between
the groups (data not shown).
Sensor accuracy
Overall sensor accuracy was very good,
with combined MARD of 8.7  1.5% and
MAD of 13.3  1.5 mg/dl. Sensors were
calibrated on average every 5.7  0.5 h.
Figure2—Exampleofdatatakenfromaclosed-loopstudy.Venousbloodglucoseisnotedbyblack
diamonds,insulindeliveryratebyagrayline,andglucagondeliveryratebyrectangles.Notethat
glucagon is delivered by algorithm in the late postprandial period at times of impending hypogly-
cemia. Overt hypoglycemia is avoided without the use of carbohydrate supplementation.
Figure 3—Summary of glucose levels (means  SE), insulin delivery rate, and, for glucagon
studies, the glucagon delivery rate. Venous blood glucose is noted by gray diamonds, insulin
delivery rate by a black line, glucagon delivery rate by a light gray line, and meals by black
triangles. A: Composite of eight insulin plus placebo studies. B: Composite of seven insulin plus
high-gain glucagon studies. Insulin delivery and overall glycemic control were similar in both
conditions.
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than sensed, glucose values were sent to
the controller due to suboptimal sensor
accuracy.
Tolerability
Only one subject developed transient
nausea and vomiting after receiving 350
g glucagon over 175 min during a low-
gain glucagon study. No subjects in the
high-gainglucagonorplacebostudiesex-
perienced any side effects.
CONCLUSIONS — In this automated
glycemic control system, we compared
the effect of subcutaneous glucagon, de-
livered in small doses at times of impend-
ing hypoglycemia, to saline placebo. In
bothconditions,thealgorithmcalledfora
signiﬁcant reduction or discontinuation
of insulin delivery during impending hy-
poglycemia. We found that compared
with placebo, glucagon delivered in
pulses using high-gain parameters signif-
icantly decreased the time spent in the
hypoglycemic range, the number of hy-
poglycemic events, and the number of
treatments needed for hypoglycemia.
Onlythehigh-gain,notthelow-gain,glu-
cagon delivery system was superior to
placebo in reducing all three of these out-
comes, despite the fact that a lower
amount of glucagon was delivered in the
high-gain studies. The high-gain gluca-
gon infusion consisted of a pulse of glu-
cagon typically given over 5–10 min at a
time of impending hypoglycemia fol-
lowed by a 50-min off period. The low-
gain glucagon was delivered in a slow,
more prolonged manner without a man-
datoryoffperiod.Thehigh-gainglucagon
infusion is arguably more physiologic, as
glucagon is secreted rapidly in response
to hypoglycemia in humans without dia-
betes (15).
Minimizing glucagon delivery, as
described here, is important to avoid po-
tential side effects, such as acute hyper-
glycemia and nausea, and more severe
effects, such as depletion of liver glyco-
gen. Notably, the mean glucose levels in
the high-gain glucagon and placebo stud-
ieswereverysimilar.However,largerand
longer-termstudieswillberequiredtoas-
sess the effect of ongoing glucagon treat-
ment on overall glycemic control.
Limitations of this study include the
absence of paired studies for some indi-
viduals. In addition, the lower amount of
premeal insulin in the low-gain glucagon
studies compared with the placebo stud-
ies may have affected the results, in par-
ticular the differences in mean and
postprandial glucose levels. In some re-
gards, the need to announce the meal to
thecontrollerandthedeliveryofsubstan-
tialamountsofpremealinsulinmightalso
be considered a limitation. A true closed-
loop system without meal announcement
using currently available insulin prepara-
tionsdeliveredsubcutaneouslyisunlikely
to provide optimal blood glucose control.
After reconstitution, glucagon forms
ﬁbrils over time (16,17) and is currently
approved for use only immediately after
reconstitution. Despite the occurrence of
ﬁbrils and aggregates, our group (9) and
El-Khatibetal.(18)haveshownthateven
whenglucagonisagedfor1weekatroom
or body temperature, large doses retain
full hyperglycemic activity in animals.
The reason that the aggregated form of
glucagon retains its physiologic effect is
unclear. It is possible that, after injection,
the aggregates dissociate into monomeric
form in the subcutaneous space.
There is some evidence that glucagon
can be cytotoxic if it is “aged” at very high
concentrations (19), but there are no re-
ports of cytotoxicity during aging at con-
centrations of 1 mg/ml or lower. Further
studiesareneededtoexaminetheefﬁcacy
of glucagon used for several days after
reconstitution and to assess potential
cytotoxicity at clinically appropriate con-
centrations. It is possible that aggregation
may be overcome using glucagon analogs
(20) or novel methods of glucagon prep-
aration (21).
In conclusion, we found that gluca-
gon given to subjects with type 1 diabetes
by algorithm during impending hypogly-
cemiaiseffectiveinpreventingmostcases
of hypoglycemia. Glycemic control was
good in this study, in part due to open-
loop insulin delivery before meals. These
results suggest that an automated system
of closed-loop glucagon delivery, with a
hybrid pattern of insulin delivery includ-
ingmealannouncement,isabletocontrol
glycemia safely and effectively in people
with type 1 diabetes. There is a need for
furtherresearchintotheissueofglucagon
stabilityandforthedevelopmentofafully
automated insulin and glucagon delivery
device.
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